Detection of FHIT and p16 mRNA Deletion in Biopsy Specimens Obtained by Bronchoscopy for the Diagnosis of Lung Cancer

2013 ◽  
Vol 28 (3) ◽  
pp. 259-266 ◽  
Author(s):  
Ping Chen ◽  
Jian Li ◽  
Yi Wang ◽  
Li-Rong Zhu ◽  
Yi-Ming Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Smoking Status ◽  
Diagnostic Value ◽  
Gene Transcript ◽  
Detection Rates ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

The purpose of this study was to investigate the diagnostic value of the deletion of fragile histidine triad (FHIT) and p16INK4a (p16) mRNA in biopsies obtained by bronchoscopy. Biopsies were analyzed using RT-PCR in 52 patients with lung cancer and 19 patients with benign lung disease. The results showed that the detection rates of FHIT and p16 gene transcript deletion were significantly higher in lung cancer patients than in patients with benign lung disease (65.4% versus 10.5%, p=0.001 and 59.6% versus 5.3%, p<0.001, respectively). The sensitivities for detecting FHIT and p16 transcript deletion in biopsies were 65.4% and 59.6% (combined 80.8%), respectively, which were markedly better than those of histology and cytology (42.3% and 34.6%, respectively; combined 57.7%). In 22 lung cancer patients with negative histology and cytology at initial bronchoscopy, FHIT and p16 mRNA loss was detected in 40.9% (9/22) and 36.4% (8/22) cases, respectively. FHIT mRNA loss was associated with smoking status in lung cancer patients. In conclusion, deletion of FHIT and p16 mRNA can be identified in biopsies obtained during bronchoscopic procedures. FHIT and p16 mRNA deletion can be used as biomarkers in the clinical diagnosis of lung cancer and may serve as adjuncts to histology and cytology in lung cancer diagnosis.

scholarly journals Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer

2018 ◽  
Vol 44 (1) ◽  
pp. 18-23 ◽  
Author(s):  
Lihong Zhang ◽  
Hongbin Wang ◽  
Xuejun Dong
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Smoking History ◽  
Lung Cancer Patients ◽  
Pathological Classification ◽  
Cancer Tissues ◽  
Antibody Levels

ABSTRACT Objective: To investigate the diagnostic value of α-enolase (ENO1) and serum ENO1 autoantibody levels in lung cancer. Methods: Immunohistochemistry staining and ELISA were performed to detect ENO1 expression in lung tissue and serum ENO1 autoantibody levels, respectively. Results: The expression of ENO1 was higher in lung cancer tissues than in benign lung disease tissues (p < 0.001). The proportion of lung cancer samples expressing ENO1 was not significantly different among the various pathological classification groups. The proportion of samples expressing ENO1 was higher in lung cancer patients in stages I/II than in those in stages III/IV (χ2 = 5.445; p = 0.018). The expression of ENO1 in lung cancer tissues was not associated with age, gender, or smoking history. Serum ENO1 antibody levels were significantly higher in the lung cancer group than in the benign lung disease and control groups (p < 0.001). The differences among the pathological classification groups were not statistically significant. Serum ENO1 antibody levels were also in lung cancer patients in stages I/II than in those in stages III/IV (p < 0.01). Serum ENO1 antibody levels were not associated with age, gender, or smoking history in lung cancer patients. The ROC curve representing the diagnosis of lung cancer based on ENO1 antibody levels had an area under the curve of 0.806. Conclusions: Our results suggest that high levels of ENO1 are associated with the clinical stage of lung cancer and that ENO1 expression and its serum autoantibody levels show diagnostic value in lung cancer.

scholarly journals Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules

2020 ◽  
Vol 146 (12) ◽  
pp. 3349-3357
Author(s):  
Yunli Huo ◽  
Zijian Guo ◽  
Xuehui Gao ◽  
Zhongjuan Liu ◽  
Ruili Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Predictive Value ◽  
Positive Test ◽  
Test Results ◽  
Newly Diagnosed ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Abstract Purpose Increasing lung cancer incidence in China with a high death rate due to late diagnosis highlights the need for biomarkers, such as panels of autoantibodies (AAbs), for prediction and early lung cancer diagnosis. We conducted a study to further evaluate the clinical performance of an AAb diagnostic kit. Methods Using enzyme-linked immunosorbent assay, levels of seven AAbs in serum samples from 121 patients with newly diagnosed lung cancer, 84 controls (34 healthy individuals and 50 patients with benign lung disease), and 100 indeterminate solid nodules, were measured. Participants were followed up until 6 months after a positive test result to confirm lung cancer diagnosis. Results The seven AAb concentration was significantly higher in lung cancer patients than in controls (P < 0.05). The seven AAb sensitivity and specificity for newly diagnosed lung cancer were 45.5% and 85.3%, respectively, while the seven AAb combined area under the curve (in lung cancer patients versus controls) was 0.660. Of the 28 patients with solid nodules with positive test results, 8 and 3 were diagnosed with lung cancer and benign lung disease, respectively, during follow-up. The positive predictive value of the experiment was 72.7%. Conclusion Positive AAb test results were associated with a high risk of lung cancer. The seven-AAb panel also had a high predictive value for detecting lung cancer in patients with solid nodules. Our seven lung cancer autoantibody types can provide an important early warning sign in the clinical setting.

scholarly journals Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Shinechimeg Dima ◽  
Kun-Huang Chen ◽  
Kung-Jeng Wang ◽  
Kung-Min Wang ◽  
Nai-Chia Teng
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Physician Visits ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Kaplan Meier ◽  
Diagnosis Of Lung Cancer

The effect of comorbidity on lung cancer patients’ survival has been widely reported. The aim of this study was to investigate the effects of comorbidity on the establishment of the diagnosis of lung cancer and survival in lung cancer patients in Taiwan by using a nationwide population-based study design. This study collected various comorbidity patients and analyzed data regarding the lung cancer diagnosis and survival during a 16-year follow-up period (1995–2010). In total, 101,776 lung cancer patients were included, comprising 44,770 with and 57,006 without comorbidity. The Kaplan–Meier analyses were used to compare overall survival between lung cancer patients with and without comorbidity. In our cohort, chronic bronchitis patients who developed lung cancer had the lowest overall survival in one (45%), five (28.6%), and ten years (26.2%) since lung cancer diagnosis. Among lung cancer patients with nonpulmonary comorbidities, patients with hypertension had the lowest overall survival in one (47.9%), five (30.5%), and ten (28.2%) years since lung cancer diagnosis. In 2010, patients with and without comorbidity had 14.86 and 9.31 clinical visits, respectively. Lung cancer patients with preexisting comorbidity had higher frequency of physician visits. The presence of comorbid conditions was associated with early diagnosis of lung cancer.

scholarly journals CHD5 may be a promising novel bio-marker for the diagnosis of lung cancer patients

2020 ◽  
Author(s):  
Jun Yang ◽  
Hua Zhong ◽  
Qinghui Yang ◽  
Jian Yu ◽  
Cailing Jin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Roc Curve ◽  
Diagnostic Value ◽  
Suppressor Gene ◽  
Smoking History ◽  
Healthy Controls ◽  
Serum Samples ◽  
Lung Cancer Patients ◽  
Diagnosis Of Lung Cancer

Abstract Background Chromodomain helicase DNA binding protein 5 (CHD5) is a new tumor suppressor gene in various types of cancer. And it is still not clear about the role of CHD5 in lung cancer. In this study, we aim to assess diagnostic value of CHD5 in patients with lung cancer. Methods CHD5 expression in 108 lung cancer serum samples and 65 healthy controls were determined by quantitative Real-Time PCR (qRT-PCR). A receiver operating characteristic (ROC) curve was established to analyze the effect of CHD5 in the diagnosis of lung cancer. Results The expression of CHD5 was significantly decreased in lung cancer samples compared with the healthy controls (P < 0.0001). Advanced TNM stage (P = 0.020), gender (P = 0.001) and smoking history (P = 0.000) were associated with the decreased CHD5 expression. Besides, the results of ROC analysis showed that the area under ROC curve (AUC) was 0.855 with a sensitivity of 87.1% and a specificity of 81.3%. Conclusions In conclusion, this study suggested that CHD5 expression is down-regulated in lung cancer. Furthermore, CHD5 expression could be a potential diagnosis bio-marker in lung cancer patients.

scholarly journals Cytological and histological diagnosis of lung cancer in Sardinia and Italy in the 1990s

2016 ◽  
Vol 67 (4) ◽  
Author(s):  
P. Pirina ◽  
M. Budroni ◽  
S. Esposito ◽  
S. Ostera ◽  
M.F. Polo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Cancer Registries ◽  
Histological Diagnosis ◽  
Cytological Diagnosis ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

Background. Up to 30-50% of all lung cancer cases remain without cyto-histological characterisation. The aim of our study was to evaluate retrospectively the proportion of histological and/or cytological diagnosis in patients with lung cancer in Sardinia. Methods. Data was gathered by consulting the hospital registers and case notes of individual patients released from hospital with a diagnosis of Lung Cancer at all medical centres throughout Sardinia. In gathering patients’ data, we focused our attention on cytological and histological procedures through which allowed the lung cancer was diagnosed. Cancer Registries data was utilised to compare our data with national and Sassari province data. Results. From 1991 to 1996 there was a total of 3146 lung cancer patients registered in Sardinia. 1902 patients (60.5%) had a histological diagnosis, 142 patients (4.5%) a cytological diagnosis while in 1102 patients (35%) the diagnosis was performed without any pathological validation. Conclusions. Our study has shown that lung cancer diagnosis is supported by pathological verification in 65% of cases while in remaining 35% of patients the diagnosis is based only on clinical and radiological reports. In Italy data from Cancer Registries report the percentage of cyto- histological diagnosis to be 70% with the percentage of cytological diagnosis being higher than in Sardinia.

scholarly journals NOB1 Assumes Signifying Capacity in Lung Cancer Diagnosis.

2020 ◽  
Author(s):  
Jun Yang ◽  
Hua Zhong ◽  
Qinghui Yang ◽  
Jian Yu ◽  
Cailing Jin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Roc Curve ◽  
Diagnostic Value ◽  
Pcr Analysis ◽  
Healthy Controls ◽  
Operating Characteristics ◽  
Chi Square ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Abstract Background: NIN1/RPN12 binding protein 1 homolog (NOB1) gene was reported to play a key role in the oncogenesis and prognosis of carcinomas. The aim of the present study was to investigate the expression of NOB1 and its clinical significance in lung cancer, and further explore the diagnostic value of NOB1 in lung cancer patients.Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was used to characterize the expression of NOB1 in 97 lung cancer patients and 55 healthy controls. The associations of NOB1 mRNA expression with clinicopathological factors of lung cancer patients were analyzed by Chi-square test. The receiver operating characteristics (ROC) curve was used to evaluate the diagnostic value of NOB1 in lung cancer.Results: The expression levels of NOB1 mRNA in lung cancer samples were significantly up-regulated compared with healthy controls (P<0.001). And the NOB1 expression was significant correlated with differentiation (P=0.005) and invasion depth (P=0.008). No associations were found between NOB1 expression and other factors (All P>0.05). ROC curve revealed that the area under ROC curve (AUC) was 0.885, with a sensitivity of 76.3% and a specificity of 89.1%. And the cutoff value of NOB1 was 2.225.Conclusion: NOB1 is a sensitive and specific diagnostic marker for lung cancer, and provide a new therapeutic target for lung cancer treatment.

Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-stage Lung Cancer Diagnosis

2020 ◽  
Author(s):  
Lingling Wan ◽  
Yutong He ◽  
Qingyi Liu ◽  
Di Liang ◽  
Yongdong Guo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Early Stage ◽  
Untargeted Metabolomics ◽  
Early Stage Lung Cancer ◽  
Lung Cancer Patients ◽  
Diagnosis Of Lung Cancer ◽  
Metabolomics Analysis ◽  
Stage Lung Cancer

Abstract Background: Lung cancer is a malignant tumor that has the highest morbidity and mortality rate among all cancers. Early diagnosis of lung cancer is a key factor in reducing mortality and improving prognosis. Methods: In this study, we performed CTC next-generation sequencing (NGS) in early-stage lung cancer patients to identify lung cancer-related gene mutations. Meanwhile, a serum liquid chromatography-tandem mass spectrometry (LC-MS) untargeted metabolomics analysis was performed in the CTC-positive patients, and the early diagnostic value of these assays in lung cancer was analyzed. Results: 62.5% (30/48) of lung cancer patients had ≥ 1 CTC. By CTC NGS, we found that > 50% of patients had 4 commonly mutated genes, namely, NOTCH1, IGF2, EGFR, and PTCH1. 47.37% (9/19) patients had ARIDH1 mutations. Additionally, 30 CTC-positive patients and 30 healthy volunteers were subjected to LC-MS untargeted metabolomics analysis. We found 100 different metabolites, and 10 different metabolites were identified through analysis, which may have potential clinical application value in the diagnosis of CTC-positive early-stage lung cancer (AUC > 0.9). Conclusions: Our results indicate that NGS of CTC and metabolomics may provide new tumor markers for the early diagnosis of lung cancer. This possibility requires more in-depth large-sample research for verification.

scholarly journals Braf and erbB2 mutations correlate with smoking status in lung cancer patients

2012 ◽  
Vol 3 (5) ◽  
pp. 771-775 ◽  
Author(s):  
HIDEFUMI SASAKI ◽  
MASAYUKI SHITARA ◽  
KEISUKE YOKOTA ◽  
KATSUHIRO OKUDA ◽  
YU HIKOSAKA ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Smoking Status ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document